The Use of Biologic Modifiers as a Bridge to Hematopoietic Cell Transplantation in Primary Immune Regulatory Disorders
Recently, primary immune regulatory disorders have been described as a subset of inborn errors of immunity that are dominated by immune mediated pathology. As the pathophysiology of disease is elucidated, use of biologic modifiers have been increasingly used successfully to treat disease mediated cl...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.692219/full |
| _version_ | 1818589218151071744 |
|---|---|
| author | Danielle E. Arnold Deepak Chellapandian Jennifer W. Leiding Jennifer W. Leiding |
| author_facet | Danielle E. Arnold Deepak Chellapandian Jennifer W. Leiding Jennifer W. Leiding |
| author_sort | Danielle E. Arnold |
| collection | DOAJ |
| description | Recently, primary immune regulatory disorders have been described as a subset of inborn errors of immunity that are dominated by immune mediated pathology. As the pathophysiology of disease is elucidated, use of biologic modifiers have been increasingly used successfully to treat disease mediated clinical manifestations. Hematopoietic cell transplant (HCT) has also provided definitive therapy in several PIRDs. Although biologic modifiers have been largely successful at treating disease related manifestations, data are lacking regarding long term efficacy, safety, and their use as a bridge to HCT. This review highlights biologic modifiers in the treatment of several PIRDs and there use as a therapeutic bridge to HCT. |
| first_indexed | 2024-12-16T09:37:09Z |
| format | Article |
| id | doaj.art-a7144cf5961d4bdcacc95d4f96ab7f8e |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-16T09:37:09Z |
| publishDate | 2021-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-a7144cf5961d4bdcacc95d4f96ab7f8e2022-12-21T22:36:23ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-06-011210.3389/fimmu.2021.692219692219The Use of Biologic Modifiers as a Bridge to Hematopoietic Cell Transplantation in Primary Immune Regulatory DisordersDanielle E. Arnold0Deepak Chellapandian1Jennifer W. Leiding2Jennifer W. Leiding3National Cancer Institute, National Institutes of Health, Bethesda, MD, United StatesCenter for Cell and Gene Therapy for Non-Malignant Conditions, Cancer and Blood Disorders Institute, Johns Hopkins All Children’s Hospital, St. Petersburg, FL, United StatesCenter for Cell and Gene Therapy for Non-Malignant Conditions, Cancer and Blood Disorders Institute, Johns Hopkins All Children’s Hospital, St. Petersburg, FL, United StatesDivision of Allergy and Immunology, Department of Pediatrics, University of South Florida, St. Petersburg, FL, United StatesRecently, primary immune regulatory disorders have been described as a subset of inborn errors of immunity that are dominated by immune mediated pathology. As the pathophysiology of disease is elucidated, use of biologic modifiers have been increasingly used successfully to treat disease mediated clinical manifestations. Hematopoietic cell transplant (HCT) has also provided definitive therapy in several PIRDs. Although biologic modifiers have been largely successful at treating disease related manifestations, data are lacking regarding long term efficacy, safety, and their use as a bridge to HCT. This review highlights biologic modifiers in the treatment of several PIRDs and there use as a therapeutic bridge to HCT.https://www.frontiersin.org/articles/10.3389/fimmu.2021.692219/fullPIRDCTLA4Pi3KinaseSTAT1STAT3Jakinib |
| spellingShingle | Danielle E. Arnold Deepak Chellapandian Jennifer W. Leiding Jennifer W. Leiding The Use of Biologic Modifiers as a Bridge to Hematopoietic Cell Transplantation in Primary Immune Regulatory Disorders Frontiers in Immunology PIRD CTLA4 Pi3Kinase STAT1 STAT3 Jakinib |
| title | The Use of Biologic Modifiers as a Bridge to Hematopoietic Cell Transplantation in Primary Immune Regulatory Disorders |
| title_full | The Use of Biologic Modifiers as a Bridge to Hematopoietic Cell Transplantation in Primary Immune Regulatory Disorders |
| title_fullStr | The Use of Biologic Modifiers as a Bridge to Hematopoietic Cell Transplantation in Primary Immune Regulatory Disorders |
| title_full_unstemmed | The Use of Biologic Modifiers as a Bridge to Hematopoietic Cell Transplantation in Primary Immune Regulatory Disorders |
| title_short | The Use of Biologic Modifiers as a Bridge to Hematopoietic Cell Transplantation in Primary Immune Regulatory Disorders |
| title_sort | use of biologic modifiers as a bridge to hematopoietic cell transplantation in primary immune regulatory disorders |
| topic | PIRD CTLA4 Pi3Kinase STAT1 STAT3 Jakinib |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.692219/full |
| work_keys_str_mv | AT danielleearnold theuseofbiologicmodifiersasabridgetohematopoieticcelltransplantationinprimaryimmuneregulatorydisorders AT deepakchellapandian theuseofbiologicmodifiersasabridgetohematopoieticcelltransplantationinprimaryimmuneregulatorydisorders AT jenniferwleiding theuseofbiologicmodifiersasabridgetohematopoieticcelltransplantationinprimaryimmuneregulatorydisorders AT jenniferwleiding theuseofbiologicmodifiersasabridgetohematopoieticcelltransplantationinprimaryimmuneregulatorydisorders AT danielleearnold useofbiologicmodifiersasabridgetohematopoieticcelltransplantationinprimaryimmuneregulatorydisorders AT deepakchellapandian useofbiologicmodifiersasabridgetohematopoieticcelltransplantationinprimaryimmuneregulatorydisorders AT jenniferwleiding useofbiologicmodifiersasabridgetohematopoieticcelltransplantationinprimaryimmuneregulatorydisorders AT jenniferwleiding useofbiologicmodifiersasabridgetohematopoieticcelltransplantationinprimaryimmuneregulatorydisorders |